Evidence map›Paper›PMID 30898362›Full record

ReviewAmerican journal of kidney diseases : the official journal of the National Kidney Foundation2019

Hypertension in CKD: Core Curriculum 2019.

Elaine Ku, Benjamin J Lee, Jenny Wei, Matthew R Weir

Registry-linked trialAbstract readReview
PubMed Publisher
In one paragraph

Review in American journal of kidney diseases : the official journal of the National Kidney Foundation, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT07309094 (Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease), which is not on this map. Cited by 284 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
284citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT07309094 recruitingstarted 2023, after this paper: background citation

Clinical, Morphometric and Biochemical Effects on Adiposopathy Associated With the Use of GLP-1 Receptor Agonists in Chronic Kidney Disease

Ran2023Enrolled250Registered outcomes15Posted comparisons0ConditionsChronic Kidney Disease Stage 1, Chronic Kidney Disease Stage 2, Chronic Kidney Disease stage3, Chronic Kidney Disease stage4ArmsGLP-1 receptor agonist, Other drugs, SGLT2 inhibitor, Tirzepatide
PMID 38785209PMID 38378894PMID 30340847PMID 19776173PMID 19896746PMID 26386043PMID 28765150PMID 31373167PMID 32061315PMID 32444271PMID 33008306PMID 34113631other papers from this trial
Open the trial in the graph
3 · Its place in the literature

Who cites it

284 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Guideline
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Review
  12. Article
  13. Article
  14. Kidney Denervation: Latest Breakthroughs and Insights.Clinical journal of the American Society of Nephrology : CJASN · 2026
    Review
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Article

224 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Elaine KuDivision of Nephrology and Pediatric Nephrology, Departments of Medicine and Pediatrics, University of California San Francisco, San Francisco, CA. Electronic address: elaine.ku@ucsf.edu.
Benjamin J LeeHouston Kidney Consultants, Houston Methodist Institute for Academic Medicine, Houston, TX.
Jenny WeiSchool of Medicine, University of Southern California, Los Angeles, CA.
Matthew R WeirDivision of Nephrology and Hypertension, Department of Medicine, University of Maryland, Baltimore, MD.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Hypertension and chronic kidney disease (CKD) are closely interlinked pathophysiologic states, such that sustained hypertension can lead to worsening kidney function and progressive decline in kidney function can conversely lead to worsening blood pressure (BP) control. The pathophysiology of hypertension in CKD is complex and is a sequela of multiple factors, including reduced nephron mass, increased sodium retention and extracellular volume expansion, sympathetic nervous system overactivity, activation of hormones including the renin-angiotensin-aldosterone system, and endothelial dysfunction. Currently, the treatment target for patients with CKD is a clinic systolic BP < 130mm Hg. The main approaches to the management of hypertension in CKD include dietary salt restriction, initiation of treatment with angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, and diuretic therapy. Uncontrolled hypertension can lead to significant cardiovascular morbidity and mortality and accelerate progression to end-stage kidney disease. Although intensive BP control has not been shown in clinical trials to slow the progression of CKD, intensive BP control reduces the risk for adverse cardiovascular outcomes and mortality in the CKD population.

Indexed as

HypertensionRenal Insufficiency, ChronicEndothelium, VascularHumansPatient Care ManagementRenin-Angiotensin Systemambulatory blood pressure monitoring (ABPM)antihypertensive agentsblood pressure (BP)BP controlcardiovascular outcomeschronic kidney disease (CKD)Hypertensionrenin-angiotensin system (RAS)review

Identifiers

PMID30898362

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.